At birth, both the innate and adaptive arms of immunity are functionally incomplete. Newborns depend heavily on maternal antibodies transferred across the placenta for passive protection, and this shield decays within months: estimated durations of maternal antibody protection are roughly 3.3 months for measles, 2.7 months for mumps, 3.9 months for rubella, and 3.4 months for varicella. Neonates can mount adaptive responses, but their capacity to generate long-lasting immunity is limited by underdeveloped germinal centers, low expression of B-cell co-receptors such as CD21, CD40, CD80, and CD86, impaired Th1 cytokine secretion, and reduced B-cell receptor signaling strength. The review emphasizes that this is not simple deficiency. The neonatal immune system operates in a tolerogenic mode, likely to prevent immunopathological damage as the infant transitions from a semi-allogeneic, sterile uterine environment into a microbe-rich world, even at the cost of vulnerability to uncontrolled pathogen proliferation.

The innate immune system, the first line of defense, is active from birth and responds within minutes to hours, but its cellular players mature on very different schedules. Neutrophils appear in fetal circulation by the end of the first trimester and surge before delivery, yet neonatal neutrophils show weak inflammatory responses, a deficit most pronounced in premature infants. Monocytes and macrophages in newborns exhibit diminished signaling and cytokine responses compared with adults, reaching normal levels within days. Crucially, the review highlights the newborn microbiome as the first teacher of the developing immune system: gut microbes induce interleukin-17 production by group 3 innate lymphoid cells, which drives granulocyte colony-stimulating factor release and neutrophil production through a Toll-like receptor 4 and MyD88-dependent pathway, maintaining systemic immune vigilance against infection.

Dendritic cells, the sentinels that bridge innate and adaptive immunity, tell a similarly staged story. Plasmacytoid dendritic cells, the body’s type I interferon factories against viruses, constitute 53 percent of the dendritic cell pool in infants, the lowest total dendritic cell proportion of any age group. Although preterm infants possess adult-like levels of TLR7 and TLR9 on these cells, they secrete low amounts of interferon-alpha and beta, leaving antiviral innate immunity ineffective relative to adults. A progressive increase in conventional dendritic cell subsets occurs during the transition from infancy to childhood, suggesting major immune remodeling early in life. In older adults, the dominant subset is cDC2 at 49 percent, while cDC1 cells expand preferentially in adulthood, possibly compensating for the age-related decline in CD8-positive T cells. Lower plasmacytoid dendritic cell proportions in healthy older people may partly explain their reduced capacity to fight viral infections.

Natural killer cells and other innate lymphoid populations undergo their own lifelong remodeling. Newborn natural killer cells have reduced cytolytic function, blunted sensitivity to interleukin-2 and interleukin-15, and lower interferon-gamma secretion, yet still provide some antiviral protection. During pregnancy, maternal peripheral natural killer cells migrate to the decidua and differentiate into non-cytotoxic cells with enhanced secretory activity, producing interferon-gamma, vascular endothelial growth factor, and placental growth factor that are critical for immune tolerance, angiogenesis, and fetal development, though their hyperactivation can trigger spontaneous abortion. With age, natural killer cells shift toward a mature CD56dimCD16-positive phenotype but become dysfunctional in cytotoxicity, degranulation, and cytokine secretion, weakening the elimination of senescent and malignant cells. Strikingly, single-cell RNA sequencing of three centenarian cohorts revealed increased peripheral natural killer cell frequencies in these exceptionally long-lived individuals, alongside reduced CD4-positive T and B cell counts.

That centenarian signature has crystallized into one of the review’s central themes: cytotoxic immunity as a marker of healthy aging. A bioinformatic algorithm developed to identify immune populations associated with longevity found that natural killer cells, CD8-positive T cells, and gamma-delta T cells correlate positively with extended lifespan, whereas inflammatory-lineage populations such as CD4-positive T cells, B cells, and dendritic cells show negative associations. Centenarian neutrophils display phagocytic and chemotactic activities comparable to those of young adults, with low superoxide anion levels and preserved glutathione, while frail middle-aged subjects show the worst profiles. Reduced complement C3 and C4 levels in centenarians contrast with the elevated levels seen in older adults at risk of metabolic syndrome and cardiovascular disease, and caloric restriction has been shown to downregulate the C3a/C3 ratio, attenuating age-related inflammation. Maintaining cytotoxic phenotypes and redox balance, the authors suggest, may be exploitable clinically to blunt immunosenescence.

The adaptive arm follows an equally dramatic arc. T lymphocytes mature in the thymus from seven to eight weeks of gestation and populate the periphery by weeks twelve to thirteen, but thymic involution drives a progressive loss of naive T cells that accelerates after age sixty. Newborns carry only about 1 percent antigen-educated T cells; in adults over sixty, that figure reaches 65 percent. The T cell receptor repertoire narrows with age, CD28 expression is lost from more than half of CD8-positive T cells, and transcriptional reprogramming pushes aging T cells toward a Th2 polarization associated with dysregulated B cell responses and reduced antibody neutralizing capacity after influenza vaccination, a failure that contributes to influenza deaths in 70 to 85 percent of elderly cases. B cells, meanwhile, peak in the first year of life at around six months before gradually declining, and in old age naive B cells are replaced by quiescent memory cells with diminished affinity maturation and class switching.

Perhaps the most conceptually provocative section concerns immunological memory itself. Long considered the exclusive property of adaptive immunity, memory-like responses have now been demonstrated in innate cells, a phenomenon termed trained immunity. Monocytes, macrophages, natural killer cells, and even bone marrow progenitors exposed to stimuli such as beta-glucan or the Bacillus Calmette-Guerin vaccine undergo epigenetic and metabolic reprogramming that confers enhanced, non-antigen-specific protection against unrelated pathogens for months. In murine models, BCG vaccination at birth improved survival in neonatal sepsis with profound remodeling of monocyte and neutrophil subsets, though some pattern recognition receptor agonists failed to protect neonatal mice against Leptospira, underscoring the risks of immunostimulation in early life. In adults over fifty in Guinea-Bissau, BCG vaccination elevated interferon-gamma and pro-inflammatory cytokine responses two months later, and some reports suggest it can reduce circulating inflammatory markers of inflammaging, although recent large trials found no boost to influenza vaccine responses and even flagged aggravation of cardiac arrhythmias as a concern.

The demographic stakes are considerable. The World Health Organization estimates that people over sixty numbered 1.2 billion in 2025 and will reach 2 billion by 2050, with 80 percent living in developing countries, while the European Union’s elderly share is projected to grow from 6.0 percent in 2021 to 14.6 percent by 2100. Immunosenescence, driven by thymic involution, naive cell depletion, inverted CD4/CD8 ratios, gut microbiota shifts that increase intestinal permeability, and the accumulation of senescent cells secreting interleukin-6, tumor necrosis factor-alpha, and interleukin-1 beta, raises vulnerability to infections, cancer, autoimmune disease, and neurodegeneration. Yet the aging immune system paradoxically resembles the newborn’s, with weakened antimicrobial activity and compromised adaptive responses at both ends of life. The Bucharest team argues that mapping these stage-specific mechanisms, from the SOX4-positive naive T cells and interferon-gamma that compensate for infant vulnerability to the cytotoxic dominance that defines centenarian immunity, provides the mechanistic foundation for age-adapted vaccines and immunotherapies capable of restoring immune function in the frail and extending healthy lifespan for everyone else.

Subject of Research: Immune system development across the human lifespan, from neonatal immaturity to immunosenescence and centenarian longevity

Article Title: Immune system ontogeny—a subtle evolution to perfection

Article References: Munteanu, A. N., Surcel, M., Dobre, E. G., Constantin, C., & Neagu, M. (2026). Immune system ontogeny—a subtle evolution to perfection. Frontiers in Aging, 7, Article 1872955. https://doi.org/10.3389/fragi.2026.1872955

Image Credits: AI Generated

DOI: 10.3389/fragi.2026.1872955

Keywords: immunosenescence, inflammaging, trained immunity, neonatal immunity, centenarians, natural killer cells, dendritic cells, T cells, B cells, immunological memory, complement system, BCG vaccine

The research team, led by Giovanni Mario Pes of the University of Sassari and including longevity researchers Steven Austad, Dan Buettner, Hiram Beltrán-Sánchez, and S. Jay Olshansky, set out to determine whether Bolotana exhibits a demographic profile compatible with a candidate longevity blue zone. The term blue zone originated from the blue markings researchers used when first mapping Sardinian longevity hotspots in the early 2000s, and it has since come to describe geographically circumscribed populations with exceptionally favorable survival relative to their national contexts. But the concept has come under pressure in recent years. Standardized reassessments suggest that the longevity advantage of some historically documented blue zones, particularly Okinawa in Japan and Nicoya in Costa Rica, has weakened over time, possibly because other populations have caught up, because late-life mortality improvements have slowed generally, or because the favorable early-life exposures that shaped early twentieth-century cohorts have faded through cohort replacement.

Against that backdrop, Bolotana offered an unusual opportunity. The village combines substantial residential continuity with remarkably complete civil and parish records stretching back generations, making rigorous age validation possible. The researchers pulled demographic information from the municipal civil registry, including sex, dates and places of birth and death, residence, and migration status, and then cross-checked civil birth records against independent parish registers of baptisms, deaths, and burials. Record linkage relied on concordance of names, dates, parentage, and family relationships, with genealogical timelines reconstructed when necessary to rule out confusion between siblings or relatives sharing the same name. Civil birth documentation was available for every identified centenarian, and 97 percent of recorded centenarian deaths were independently verified against parish archives. No centenarian case had to be excluded for insufficient age documentation.

The core of the analysis is a pair of period life-table indicators built from deaths and person-years of exposure aggregated over 2021 to 2025. The first is remaining life expectancy at age 70, written e70, which measures how many additional years a person who reaches 70 can expect to live under the mortality conditions of the observation period. The second is conditional survival from age 70 to exact age 100, or S(70→100), the probability that a 70-year-old survives three more decades. Because Bolotana is small, the researchers quantified statistical uncertainty with a parametric Poisson bootstrap: in each of 20,000 replications, death counts at each single year of age from 70 to 99 were regenerated from fitted Poisson distributions while observed person-years of exposure were held fixed, a complete life table was rebuilt, and the two indicators were extracted. The 2.5th and 97.5th percentiles of the resulting distributions defined the 95 percent confidence limits. The mortality rate in the open interval at age 100 and older was deliberately held fixed, since resampling the handful of deaths in that terminal range could produce zero-death scenarios in which the life table could not be closed.

The headline results concern women. During 2021 to 2025, remaining life expectancy at age 70 for Bolotana women was 20.85 years, with a 95 percent confidence interval of 19.42 to 22.43 years. That figure exceeds not only the contemporary means for Nuoro Province (18.61 years), Sardinia as a whole (18.40 years), and Italy (18.06 years), but also the highest annual value recorded in each of those reference populations. Even more dramatic is conditional survival to age 100: 13.83 percent of Bolotana women who reach 70 are estimated to live to 100, with a confidence interval of 7.33 to 23.75 percent. That is more than three times the corresponding figures for Nuoro Province (4.33 percent), Sardinia (4.43 percent), and Italy (3.54 percent), and more than three times the value for women in the United States. Among the international benchmarks drawn from the Human Mortality Database, Bolotana women ranked second only to Hong Kong on both indicators.

Men in Bolotana also fared well, though less spectacularly. Their remaining life expectancy at age 70 was 16.02 years (95 percent CI, 14.55 to 17.79), modestly above the means for Nuoro Province, Sardinia, and Italy, and their conditional survival to 100 was 4.92 percent (95 percent CI, 1.58 to 12.76), higher than any annual value observed in the three reference populations, which ranged from 1.41 to 1.74 percent. The much wider confidence interval around the male survival estimate reflects the hard statistical reality of estimating extreme-age survival in a small population: during the five-year window, Bolotana recorded 149 deaths at ages 70 and older, 69 in men and 80 in women, and 19 residents reached age 100, five men and fourteen women, six of whom were still alive at the end of follow-up. The authors are careful to note that because the reference values are descriptive annual summaries rather than inferential estimates, these comparisons should not be read as formal tests of statistical significance.

How robust are these numbers? The team stress-tested them from several directions. An alternative constant-force-of-mortality specification for converting central mortality rates into annual death probabilities produced essentially identical results, with survival estimates differing by less than 0.10 percentage points. A binomial Monte Carlo procedure, built on Chiang’s Bernoulli-trial framework, yielded uncertainty intervals very similar to the Poisson bootstrap. Extending the observation window to include 2020, the first year of the COVID-19 pandemic, produced modest reductions, with female life expectancy at 70 falling from 20.85 to 20.37 years and female survival to 100 dropping from 13.83 to 12.48 percent, but the pronounced female advantage persisted. The most consequential sensitivity check, however, was temporal. When the researchers repeated the analysis for the period-matched window of 2015 to 2019, Bolotana’s late-life survival profile was distinctly less favorable, particularly for survival to age 100: male e70 fell to 13.87 years and male S(70→100) to just 0.77 percent, while female values were 18.30 years and 1.46 percent, all well below the original Sardinian Blue Zone’s published 2015 to 2019 estimates.

That period sensitivity is the study’s central caution. Comparing Bolotana’s 2021 to 2025 estimates with the pooled 2015 to 2019 figures for the fourteen municipalities of the original Sardinian Blue Zone shows Bolotana women ahead on both indicators, 20.85 versus 20.30 years of life expectancy at 70 and 13.83 versus 8.76 percent survival to 100, while Bolotana men trail slightly. But because those estimates come from different calendar periods, the authors treat them strictly as a historical benchmark rather than evidence of superiority. The 2015 to 2019 sensitivity analysis, which required grouping the sparse oldest-age data into five-year age bands under a constant-force assumption, suggests that Bolotana’s apparent advantage is partly a feature of the specific window examined. Short calendar periods, small populations, and stochastic variation in deaths at extreme ages all conspire to make any single five-year estimate fragile.

A complementary cohort-based analysis adds historical depth. The researchers calculated the Extreme Longevity Index for everyone born in Bolotana between 1900 and 1925: of 3,060 registered live births, 38 individuals were documented as reaching age 100, an index of 1,242 centenarians per 100,000 live births, with an exact 95 percent confidence interval of 880 to 1,701. The comparable reported Italian figure is 793 per 100,000. Because the index measures realized survival from birth, it is shaped by early- and midlife mortality as well as survival at advanced ages, and incomplete follow-up of the roughly 3 percent of emigrants who could not be traced to a documented death may have slightly understated it. Still, it points to a long-standing local propensity for centenarian survival that predates the current observation window.

What explains the pattern remains an open question. The authors list plausible contributors to the female survival advantage, including genetic background, dietary patterns, physical activity, family support, social cohesion, continuity of residence, and access to care, but the demographic data alone cannot determine whether any of these factors actually drove the observed numbers. Bolotana’s mountainous setting and low density may also have shaped its pandemic-era exposure, though the absence of individual-level data on infection, vaccination, and cause of death prevents testing that idea. The study’s limitations are candidly acknowledged: a small population, wide confidence intervals, a short observation period overlapping COVID-19, and descriptive rather than inferential comparisons. Taken together, the age validation, the life-table estimates, and the sensitivity analyses support considering Bolotana a candidate longevity blue zone, with a distinctive, predominantly female profile that contrasts with the male-centered pattern of the original Sardinian hotspot. But the evidence does not yet justify calling it an established one. Longer observation, continued demographic validation, and individual-level comparative studies will be needed to determine whether this mountain village’s exceptional survival is a durable feature of the community or a fleeting alignment of cohort and calendar.

Subject of Research: Demographic analysis of exceptional late-life survival and centenarian prevalence in Bolotana, Sardinia, as a candidate longevity blue zone

Article Title: A new blue zone? exceptional late-life survival in Bolotana, Sardinia

Article References: Pes, G. M., Austad, S. N., Buettner, D., Pedde, S., Romerio, V., Beltrán-Sánchez, H., & Olshansky, S. J. (2026). A new blue zone? exceptional late-life survival in Bolotana, Sardinia. Frontiers in Aging, 7, Article 1951042. https://doi.org/10.3389/fragi.2026.1951042

Image Credits: AI Generated

DOI: 10.3389/fragi.2026.1951042

Keywords: blue zones, exceptional longevity, Sardinia, Bolotana, life expectancy, centenarians, late-life survival, period life tables, demography, extreme longevity index, aging research, small populations

The numbers at the heart of the study are striking. Researchers estimated that 13.8 percent of women in Bolotana who reach age 70 will go on to live to 100. By comparison, approximately 3.5 percent of women in Italy and 3.6 percent of women in the United States who reach 70 survive to their hundredth birthday. That gap, nearly a fourfold difference relative to two wealthy industrialized benchmarks, is precisely the kind of signal that longevity researchers look for when evaluating whether a community deserves blue zone status. The concept originated from studies of communities where residents routinely outlive people in surrounding regions, and other blue zones confirmed by researchers include Okinawa in Japan and the Nicoya peninsula in Costa Rica.

To evaluate whether Bolotana meets that standard, the team assessed two key demographic measures: life expectancy at age 70 and the probability that a person who reaches age 70 will survive to age 100. Bolotana first attracted attention because of its unusual concentration of centenarians. In 2024, six people aged 100 or older were living in the village, a prevalence the researchers estimate to be roughly 11 times higher than that of the United States. The team then conducted a deeper analysis using civil records and church archives to reconstruct the life histories of residents across more than a century, documenting 38 centenarians among 3,060 people born in Bolotana between 1900 and 1925.

What sets this study apart from many previous claims of exceptional longevity is the rigor of its age validation, a persistent problem in a field where inflated or mistaken ages have repeatedly undermined celebrated cases. The researchers matched birth, death and baptismal records to independently verify the ages of centenarians, drawing on municipal and baptismal records that date back centuries. Olshansky emphasized that the historical record in Bolotana allows ages at birth and death to be definitively evaluated. Every person in the cohort who lived past 100 could be validated through these documents, leaving no ambiguity about whether the reported ages are genuine. That level of documentary certainty is rare and gives the findings unusual weight.

The results are also notable because they complicate an established narrative about Sardinian longevity. The island’s original blue zone, identified more than two decades ago, is famous for unusually high male longevity, a pattern that has long puzzled demographers since females almost always outlive males everywhere else in the world. In Bolotana, however, women emerged as the standout group. Female residents who reached age 70 were estimated to have nearly 21 years of additional life expectancy. Among international longevity benchmarks, Bolotana women ranked second only to Hong Kong in both life expectancy at age 70 and the probability of surviving to age 100. Olshansky suggested that this may be the longest-lived female population in the world, or close to it.

The timing of the study matters as well. In recent years, some critics have argued that many reports of extreme longevity around the world are artifacts of inaccurate records, pension fraud, or sloppy demographic data rather than genuine biology. Those critiques have cast doubt on several celebrated longevity claims and have made rigorous validation the central test for any new blue zone candidate. Bolotana’s extensive municipal and church archives allowed the researchers to validate ages through multiple independent sources, directly addressing the most common objection raised against longevity hotspots. In effect, the village offers a natural experiment in which the demographic signal of exceptional survival can be separated from the noise of unreliable record-keeping.

While the study confirms that something unusual is happening in Bolotana, it does not explain why. The village does, however, offer several clues that the researchers consider worth further investigation. Residents live in a highly walkable community built on steep streets and hills, so everyday movement is largely done by walking rather than driving. Most food is grown locally, including olive oil rich in healthy fats, a dietary staple long associated with Mediterranean patterns of eating. Families often live close together, and social isolation appears to be rare. Olshansky described a close-knit community in which people take care of one another, a social texture that gerontologists increasingly view as a meaningful contributor to healthy aging rather than a mere backdrop to it.

Researchers believe that factors such as diet, physical activity, family support, social connection and genetics likely all contribute to the village’s remarkable survival statistics. Disentangling those threads is the next scientific challenge. Genetic contributions to longevity are well documented in Sardinia, where historical isolation has produced distinctive population structure, but lifestyle and social factors are also plausible drivers of late-life survival. The study’s demographic methods, which focus on survival conditional on reaching age 70, are designed to capture the combined effect of all such influences on the oldest segment of the population, and they provide a template that other communities hoping to substantiate longevity claims can follow.

For Olshansky, the broader significance of the work extends well beyond a single Sardinian village. If researchers can identify the characteristics behind this longevity and help people elsewhere adopt them, he argues, the rest of the world can benefit from understanding the values practiced by these communities. The finding that a small mountain village can nearly quadruple the odds that a 70-year-old woman becomes a centenarian, relative to the United States, is a vivid reminder that lifespan is shaped not only by genes and medicine but by the design of towns, the food systems that feed them, and the social bonds that hold them together. As the search for the biology and sociology of exceptional aging continues, Bolotana now stands as one of the most compelling and best-documented natural laboratories on Earth.

Subject of Research: Exceptional late-life survival and centenarian prevalence in Bolotana, Sardinia, as a candidate new blue zone

Article Title: Sardinian village may be a new longevity hotspot, UIC research finds

Article References: Sardinian village may be a new longevity hotspot, UIC research finds. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: longevity, blue zones, Sardinia, Bolotana, centenarians, demography, age validation, life expectancy, epidemiology, healthy aging, Frontiers in Aging, women's longevity